<?xml version='1.0' encoding='utf-8'?>
<document id="32231067"><sentence text="Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme." /><sentence text="Ensartinib (X-396) is a promising tyrosine kinase inhibitor currently undergoing advanced clinical evaluation for the treatment of non-small cell lung cancer"><entity charOffset="0-10" id="DDI-PubMed.32231067.s2.e0" text="Ensartinib" /><entity charOffset="34-42" id="DDI-PubMed.32231067.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.32231067.s2.e0" e2="DDI-PubMed.32231067.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32231067.s2.e0" e2="DDI-PubMed.32231067.s2.e1" /></sentence><sentence text=" In this work, we investigate possible interactions of this promising drug candidate with ATP-binding cassette (ABC) drug efflux transporters and cytochrome P450 biotransformation enzymes (CYPs), which play major roles in multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs)" /><sentence text=" Accumulation studies showed that ensartinib is a potent inhibitor of ABCB1 and ABCG2 transporters" /><sentence text=" Additionally, incubation experiments with recombinant CYPs showed that ensartinib significantly inhibits CYP3A4 and CYP2C9" /><sentence text=" Subsequent molecular docking studies confirmed these findings" /><sentence text=" Drug combination experiments demonstrated that ensartinib synergistically potentiates the antiproliferative effects of daunorubicin, mitoxantrone, and docetaxel in ABCB1, ABCG2, and CYP3A4-overexpressing cellular models, respectively"><entity charOffset="120-132" id="DDI-PubMed.32231067.s7.e0" text="daunorubicin" /><entity charOffset="134-146" id="DDI-PubMed.32231067.s7.e1" text="mitoxantrone" /><entity charOffset="152-161" id="DDI-PubMed.32231067.s7.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.32231067.s7.e0" e2="DDI-PubMed.32231067.s7.e0" /><pair ddi="false" e1="DDI-PubMed.32231067.s7.e0" e2="DDI-PubMed.32231067.s7.e1" /><pair ddi="false" e1="DDI-PubMed.32231067.s7.e0" e2="DDI-PubMed.32231067.s7.e2" /><pair ddi="false" e1="DDI-PubMed.32231067.s7.e1" e2="DDI-PubMed.32231067.s7.e1" /><pair ddi="false" e1="DDI-PubMed.32231067.s7.e1" e2="DDI-PubMed.32231067.s7.e2" /></sentence><sentence text=" Advantageously, ensartinib's antitumor efficiency was not compromised by the presence of MDR-associated ABC transporters, although it acted as a substrate of ABCB1 in Madin-Darby Canine Kidney II (MDCKII) monolayer transport assays" /><sentence text=" Finally, we demonstrated that ensartinib had no significant effect on the mRNA-level expression of examined transporters and enzymes in physiological and lung tumor cellular models" /><sentence text=" In conclusion, ensartinib may perpetrate clinically relevant pharmacokinetic DDIs and modulate ABCB1-, ABCG2-, and CYP3A4-mediated MDR" /><sentence text=" The in vitro findings presented here will provide a valuable foundation for future in vivo investigations" /><sentence text="" /></document>